Celcuity, Inc.
CELC Healthcare Biotechnology
- EPS
- −38.5%
- Free cash flow
- −53.3%
- Total debt
- +658.7%
Quarter to June 2026, against a year earlier
Follow CELC
Alert me
Celcuity, Inc. (CELC) Total debt
Celcuity, Inc.'s total debt at the end of fiscal 2025 was $321.9M, up 229.3% from $97.7M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $753.2M. Over the past ten years it has ranged from $8.3K (fiscal 2020) to $321.9M (fiscal 2025) — the current reading is the highest in ten years. Celcuity, Inc. ranks 19th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $321.9M | 229.34% |
| FY2024 | $97.7M | 163.87% |
| FY2023 | $37.0M | 5.87% |
| FY2022 | $35.0M | 139.15% |
| FY2021 | $14.6M | 176,145.78% |
| FY2020 | $8.3K | (41.13%) |
| FY2019 | $14.1K | (29.15%) |
| FY2018 | $19.9K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $753.2M | 132.89% |
| Mar 2026 | $323.4M | 0.49% |
| Dec 2025 | $321.9M | 0.50% |
| Sep 2025 | $320.2M | 222.58% |
| 29 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| CELC Celcuity, Inc. | $753.2M |
| TLX Telix Pharmaceuticals Limited compare | $575.9M |
| VKTX Viking Therapeutics, Inc. compare | $250.7M |
| VRDN Viridian Therapeutics, Inc. compare | $242.2M |
| DYN Dyne Therapeutics, Inc. compare | $213.5M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $72.9M |
| DNLI Denali Therapeutics Inc. compare | $5.4M |
| IDYA IDEAYA Biosciences, Inc. compare | $2.1M |
| ELVN Enliven Therapeutics, Inc. compare | $445.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt